{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:06:10Z","timestamp":1789596370585,"version":"build-2803163510"},"reference-count":29,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["RIA2019-2888-TRIAD"],"award-info":[{"award-number":["RIA2019-2888-TRIAD"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,9,24]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The TriAD study will assess the Xpert MTB\/XDR (Xpert XDR; Cepheid) assay to detect tuberculosis (TB) drug resistance in sputum testing positive for TB to rapidly triage and treat patients with a short all-oral treatment regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      In this study, approximately 4800 Xpert MTB\/RIF or Ultra MTB-positive patients (irrespective of rifampicin (RIF) resistance (RR) status) from several clinical sites across South Africa, Nigeria and Ethiopia will be enrolled over 18\u201324 months and followed-up for approximately 6\u2009months post-TB treatment completion. Participants will be enrolled into one of two cohorts based on Xpert MTB\/RIF and Xpert XDR results:\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      (\n                      <jats:italic>M.tb<\/jats:italic>\n                      ) positive participants with RR in Cohort 1 (n=880) and\n                      <jats:italic>M.tb<\/jats:italic>\n                      positive RIF susceptible TB patients with isoniazid mono-resistance irrespective of presence of resistance to fluoroquinolones, second-line injectable drugs or ethionamide in Cohort 2 (n=400). Cohort 1 will be compared with historical cohorts from each implementing sites. The primary study outcomes include time to initiation of an appropriate treatment regimen by resistance profile and the proportion of patients with favourable treatment outcomes compared with historical cohorts from each of the implementing sites. Secondary outcomes include feasibility, acceptability and cost-effectiveness of this approach to inform policies and guidelines for programmatic implementation of this triage and treat model for drug-resistant tuberculosis management. Utility of the tuberculosis molecular bacterial load assay (TB-MBLA) for real-time treatment response assessment will also be evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC) and local research committees have provided ethical review and approval (BREC\/00002654\/2021, HREC 210805, NHREC\/01\/01\/2007 and EPHI-IRB-459\u20132022). The South African Health Products Regulatory Authority (SAHPRA) have granted regulatory approval for the TRiAD Study (SAHPRA MD20211001). Trial results will be disseminated through conference presentations, peer-reviewed publications and the clinical trial registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      Clinicaltrials.gov; Trial registration number:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05175794\">NCT05175794<\/jats:ext-link>\n                      ; South African National Clinical Trials Register (SANCTR DOH-27-012022-4720)\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-084722","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T04:31:20Z","timestamp":1732768280000},"page":"e084722","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Triage test for all-oral drug-resistant tuberculosis (DR-TB) regimen: a phase IV study to assess effectiveness, feasibility, acceptability and cost-effectiveness of the Xpert MTB\/XDR assay for rapid triage and treatment of DR-TB"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05175794","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05175794","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Kogieleum","family":"Naidoo","sequence":"first","affiliation":[{"name":"Centre for the Aids Programme of Research in South Africa, Durban, KwaZulu-Natal, South Africa"},{"name":"SAMRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9550-9501","authenticated-orcid":false,"given":"Anushka","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Centre for the Aids Programme of Research in South Africa, Durban, KwaZulu-Natal, South Africa"},{"name":"SAMRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alash'le G","family":"Abimiku","sequence":"additional","affiliation":[{"name":"International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria"},{"name":"University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2071-3038","authenticated-orcid":false,"given":"Everdina W","family":"Tiemersma","sequence":"additional","affiliation":[{"name":"Koninklijke Nederlandse Centrale Vereniging tot Bestrijding der Tuberculose, The Hague, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Gebhard","sequence":"additional","affiliation":[{"name":"Koninklijke Nederlandse Centrale Vereniging tot Bestrijding der Tuberculose, The Hague, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine M","family":"Hermans","sequence":"additional","affiliation":[{"name":"Amsterdam UMC location University of Amsterdam, Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J","family":"Sloan","sequence":"additional","affiliation":[{"name":"University of St Andrews, St Andrews, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Ruhwald","sequence":"additional","affiliation":[{"name":"Foundation for Innovative New Diagnostics, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia B","family":"Georghiou","sequence":"additional","affiliation":[{"name":"Foundation for Innovative New Diagnostics, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evaezi","family":"Okpokoro","sequence":"additional","affiliation":[{"name":"International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aderonke","family":"Agbaje","sequence":"additional","affiliation":[{"name":"International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalkidan","family":"Yae","sequence":"additional","affiliation":[{"name":"Koninklijke Nederlandse Centrale Vereniging tot Bestrijding der Tuberculose, Addis Ababa, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getachew","family":"Tollera","sequence":"additional","affiliation":[{"name":"Ethiopian Public Health Institute, Addis Ababa, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shewki","family":"Moga","sequence":"additional","affiliation":[{"name":"Ethiopian Public Health Institute, Addis Ababa, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelise","family":"Feyt","sequence":"additional","affiliation":[{"name":"Clinical HIV Research Unit (CHRU), Jose Pearson TB Hospital, Wits Health Consortium Pty Ltd, Port Elizabeth, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takondwa","family":"Kachoka","sequence":"additional","affiliation":[{"name":"Clinical HIV Research Unit (CHRU), Jose Pearson TB Hospital, Wits Health Consortium Pty Ltd, Port Elizabeth, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marothi P","family":"Letsoalo","sequence":"additional","affiliation":[{"name":"Centre for the Aids Programme of Research in South Africa, Durban, KwaZulu-Natal, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M","family":"Cabibbe","sequence":"additional","affiliation":[{"name":"Emerging bacterial pathogens, Ospedale San Raffaele, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubeshan","family":"Perumal","sequence":"additional","affiliation":[{"name":"Centre for the Aids Programme of Research in South Africa, Durban, KwaZulu-Natal, South Africa"},{"name":"SAMRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5192-0072","authenticated-orcid":false,"given":"Letitia","family":"Shunmugam","sequence":"additional","affiliation":[{"name":"Centre for the Aids Programme of Research in South Africa, Durban, KwaZulu-Natal, South Africa"},{"name":"SAMRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela M","family":"Cirillo","sequence":"additional","affiliation":[{"name":"Emerging bacterial pathogens, Ospedale San Raffaele, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah","family":"Foraida","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4742-2791","authenticated-orcid":false,"given":"Wilber","family":"Sabiiti","sequence":"additional","affiliation":[{"name":"University of St Andrews, St Andrews, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyanda Elias","family":"Ntinginya","sequence":"additional","affiliation":[{"name":"National Institute for Medical Research, Dar es Salaam, United Republic of Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bariki","family":"Mtafya","sequence":"additional","affiliation":[{"name":"National Institute for Medical Research, Dar es Salaam, United Republic of Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Bedru","sequence":"additional","affiliation":[{"name":"Koninklijke Nederlandse Centrale Vereniging tot Bestrijding der Tuberculose, Addis Ababa, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H","family":"Gillespie","sequence":"additional","affiliation":[{"name":"University of St Andrews, St Andrews, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"2025121411432147000_14.11.e084722.1","unstructured":"World Health Organization . Global Tuberculosis Report. 2018."},{"key":"2025121411432147000_14.11.e084722.2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003008","article-title":"Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data","volume":"17","author":"Dean","year":"2020","journal-title":"PLoS Med"},{"key":"2025121411432147000_14.11.e084722.3","unstructured":"World Health Organization . Global Tuberculosis Report. 2020."},{"key":"2025121411432147000_14.11.e084722.4","unstructured":"World Health Organization . The end TB strategy. 2015."},{"key":"2025121411432147000_14.11.e084722.5","unstructured":"World Health Organization . Global Tuberculosis Report. 2022."},{"key":"2025121411432147000_14.11.e084722.6","unstructured":"WHO Consolidated Guidelines on Tuberculosis . Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva: WHO Press - World Health Organization, 2022."},{"key":"2025121411432147000_14.11.e084722.7","unstructured":"World Health Organization . Largest ever roll-out of GeneXpert rapid TB test machines, Available: https:\/\/www.who.int\/news\/item\/11-06-2013-largest-ever-roll-out-of-genexpert-rapid-tb-test-machines-in-21-countries"},{"key":"2025121411432147000_14.11.e084722.8","unstructured":"Next-generation Xpert MTB\/RIF Ultra assay recommended by WHO: WHO Global TB Programme NewsFlash. 2017. Available: https:\/\/www.tbonline.info\/posts\/2017\/3\/27\/next-generation-xpert-mtbrif-ultra-assay-recommend\/"},{"key":"2025121411432147000_14.11.e084722.9","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00259-22","article-title":"Clinical Evaluation of a Line-Probe Assay for Tuberculosis Detection and Drug-Resistance Prediction in Namibia","volume":"10","author":"G\u00fcnther","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2025121411432147000_14.11.e084722.10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.870768","article-title":"Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review","volume":"13","author":"Yusoof","year":"2022","journal-title":"Front Immunol"},{"key":"2025121411432147000_14.11.e084722.11","doi-asserted-by":"crossref","DOI":"10.1038\/srep17850","article-title":"The diagnostic accuracy of the MTBDRplus and MTBDRsl assays for drug-resistant TB detection when performed on sputum and culture isolates","volume":"6","author":"Tomasicchio","year":"2016","journal-title":"Sci Rep"},{"key":"2025121411432147000_14.11.e084722.12","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02919-20","article-title":"Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates","volume":"60","author":"Kaniga","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2025121411432147000_14.11.e084722.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30407-8"},{"key":"2025121411432147000_14.11.e084722.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614915"},{"key":"2025121411432147000_14.11.e084722.15","doi-asserted-by":"crossref","first-page":"02314","DOI":"10.1128\/JCM.02314-20","article-title":"Xpert MTB\/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum","volume":"59","author":"Cao","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2025121411432147000_14.11.e084722.16","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection. 2021."},{"key":"2025121411432147000_14.11.e084722.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30691-6"},{"key":"2025121411432147000_14.11.e084722.18","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03616-2020","article-title":"New Xpert MTB\/XDR: added value and future in the field","volume":"56","author":"Bainomugisa","year":"2020","journal-title":"Eur Respir J"},{"key":"2025121411432147000_14.11.e084722.19","doi-asserted-by":"crossref","unstructured":"Gillespie SH , Sabiiti W , Oravcova K . Mycobacterial load assay. Diagn Bacteriol Methods Protoc 2017;89\u2013105. doi:10.1007\/978-1-4939-7037-7_5","DOI":"10.1007\/978-1-4939-7037-7_5"},{"key":"2025121411432147000_14.11.e084722.20","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.992451","article-title":"Systematic assessment of clinical and bacteriological markers for tuberculosis reveals discordance and inaccuracy of symptom-based diagnosis for treatment response monitoring","volume":"9","author":"Mtafya","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025121411432147000_14.11.e084722.21","doi-asserted-by":"crossref","unstructured":"Mtafya B , Sabiiti W , Sabi I , et al . Clinical evaluation of the novel molecular bacterial load assay for real-time monitoring of tuberculosis treatment response. Access Microbiol 2019;1. doi:10.1099\/acmi.ac2019.po0137","DOI":"10.1099\/acmi.ac2019.po0137"},{"key":"2025121411432147000_14.11.e084722.22","doi-asserted-by":"crossref","first-page":"02927","DOI":"10.1128\/JCM.02927-20","article-title":"Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania","volume":"59","author":"Mbelele","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2025121411432147000_14.11.e084722.23","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2019.101864","article-title":"Comparison of the Mycobacterium tuberculosis molecular bacterial load assay, microscopy and GeneXpert versus liquid culture for viable bacterial load quantification before and after starting pulmonary tuberculosis treatment","volume":"119","author":"Hai","year":"2019","journal-title":"Tuberculosis (Edinb)"},{"key":"2025121411432147000_14.11.e084722.24","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01128-14"},{"key":"2025121411432147000_14.11.e084722.25","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00547-11"},{"key":"2025121411432147000_14.11.e084722.26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(17)30079-6","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","volume":"5","author":"Dheda","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2025121411432147000_14.11.e084722.27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40258-017-0352-8","article-title":"Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis","volume":"16","author":"Schnippel","year":"2018","journal-title":"Appl Health Econ Health Policy"},{"key":"2025121411432147000_14.11.e084722.28","doi-asserted-by":"publisher","DOI":"10.3310\/hta19880"},{"key":"2025121411432147000_14.11.e084722.29","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-018-3013-0","article-title":"Cost analysis of rapid diagnostics for drug-resistant tuberculosis","volume":"18","author":"Groessl","year":"2018","journal-title":"BMC Infect Dis"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-084722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:43:28Z","timestamp":1765741408000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-084722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,27]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/bmjopen-2024-084722"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-084722","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}